Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Rigel Pharmaceuticals stock

Learn how to easily invest in Rigel Pharmaceuticals stock.

Rigel Pharmaceuticals is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 165 staff and has a trailing 12-month revenue of around $85.9 million.

How to buy Rigel Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – RIGL. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Rigel Pharmaceuticals stock price (NASDAQ: RIGL)

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

Information last updated 2023-01-25.
Latest market close$1.91
52-week range$0.64 - $3.52
50-day moving average $1.14
200-day moving average $1.41
Wall St. target price$3.66
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.50

Buy Rigel Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the close of $1.91 from 2023-01-25

1 week (2023-01-20) -4.50%
1 month (2022-12-27) 54.03%
3 months (2022-10-27) 169.01%
6 months (2022-07-27) 50.39%
1 year (2022-01-25) -21.40%
2 years (2021-01-27) -46.05%
3 years (2020-01-27) 2.46
5 years (2018-01-26) 4.32

Rigel Pharmaceuticals financials

Revenue TTM $85.9 million
Gross profit TTM $72.4 million
Return on assets TTM -32.7%
Return on equity TTM -553.79%
Profit margin -96.21%
Book value $-0.12
Market capitalisation $331 million

TTM: trailing 12 months

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $0.64 up to $3.52. A popular way to gauge a stock's volatility is its "beta".

RIGL.US volatility(beta: 0.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 0.736. This would suggest that Rigel Pharmaceuticals's shares are less volatile than average (for this exchange).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc. , a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, its other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. Rigel Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Rigel Pharmaceuticals is owned by insiders or institutions?
Currently 1.198% of Rigel Pharmaceuticals shares are held by insiders and 76.346% by institutions.
How many people work for Rigel Pharmaceuticals?
Latest data suggests 165 work at Rigel Pharmaceuticals.
When does the fiscal year end for Rigel Pharmaceuticals?
Rigel Pharmaceuticals's fiscal year ends in December.
Where is Rigel Pharmaceuticals based?
Rigel Pharmaceuticals's address is: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080
What is Rigel Pharmaceuticals's ISIN number?
Rigel Pharmaceuticals's international securities identification number is: US7665596034
What is Rigel Pharmaceuticals's CUSIP number?
Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site